We highlight differential expression of STAT3/HIF1 α and C/EBPβ in the CD33+ and CD11b+ subsets, respectively, that may aid other investigators in therapeutic targeting, subset expansion, or MDSC monitoring in cancer patients. Here, ITGAM is linked to cancer.